Product Images Clopidogrel

Clopidogrel is a medication available in 75 mg tablets, packaged in a quantity of 90. It is an RX-only drug with a particular NDC number, expiration date, and LOT number. The medicine is manufactured by Accord in North Carolina and repackaged by RemedyRepack Inc. The directions for usage can be found inside the package insert, and the medication should be kept out of children's reach. It should be stored between 20-25°C (58-77°F) with slight excursions permitted to 15-30°C (59-86°F).*

Clopidogrel is a medication that comes in the form of tablets of 75mg each. The packaging includes 30 tablets and the label indicates it is only available through prescription. The medication is produced by Accord, a manufacturer located in Durham, NC 27703. The label strongly advises to keep the medication out of the reach of children and provides directions on how to use it, which can be found in the package insert. The medication should be stored between 20-25°C, with temporary excursions permitted at 15-30°C, as indicated by USP guidelines. The product has been repackaged by RemedyRepack Inc. located in Indiana, PA 15701.*

Clopidogrel is a medication that is available in tablet form with a strength of 75 mg. One package contains 30 tablets and this medicine required a prescription to purchase. The lot number and source NDC number are provided on the package along with the manufacturer details, which is Accord located in Durham, NC. The medication needs to be stored within 20-25°C or 58-77°F temperature range, with excursions permitted to 15-30°C or 59-86°F as per USP standards. The package insert contains the details of the usage of this medicine. RemedyRepack Inc., located in Indiana, PA, has repackaged this medicine.*

This is a graph that represents the cumulative event rate of fatal or non-fatal vascular events over a follow-up period of 36 months. The graph compares the effectiveness of Aspirin and Clopidogrel Bisulfate and indicates a statistically significant difference between the two.*

This appears to be a table or graph showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for patients taking the placebo versus clopidogrel bisulfate (+ aspirin). The months of follow-up are displayed along the x-axis, with corresponding percentages on the y-axis. The asterisk indicates that other standard therapies were used as appropriate. The P-value of 0.00009 suggests a statistically significant difference in event rates between the two groups.*

This appears to be a tabular data that captures the medical history of some patients and the effects of various drugs on them, along with some statistical measurements. Without additional context, it is difficult to provide any further details.*

The text describes the mortality rates observed in a clinical trial for a placebo versus a drug called Clopidogrel. The data shows that the use of Clopidogrel resulted in 7% fewer deaths compared to the placebo, with a statistically significant p-value of 0.03. The time frame of the study was up to 28 days since randomization.*

This text appears to be a table, displaying the percentage of patients that experienced death, re-infarction, or stroke before their first discharge for a placebo group (10.1%) compared to a group treated with clopidogrel (9.2%). There is also a note indicating a 9% proportional risk reduction with clopidogrel and a p-value of 0.002. The meaning of the numbers T4, 5, and %5 is not clear from this text and may be an error in the .*

This appears to be a table displaying data related to a comparison between Clopidogrel and Aspirin as treatments for stroke and PAD (peripheral artery disease). The table includes information on the number of participants (overall) and the percentage of those treated with each medication. It also includes a section on "Favors" which may indicate which medication was more effective or beneficial. The last section shows a "Hazard Ratio" but it is unclear what this refers to without additional context.*